Key clinical point: Satralizumab monotherapy reduces the rate of neuromyelitis optica spectrum disorder relapse, compared with placebo.

Major finding: The proportion of patients who relapsed was smaller among patients who received satralizumab, compared with patients who received placebo (30% vs. 50%). The hazard ratio was 0.45.

Study details: A randomized, double-blind, placebo-controlled phase 3 trial that enrolled 95 patients with neuromyelitis optica spectrum disorder.

Disclosures: SakuraStar was funded by Chugai Pharmaceutical, a member of the Roche group. Authors reported grants, personal fees, and nonfinancial support from Chugai Pharmaceutical, and several coauthors were employees of Chugai Pharmaceutical.